DeepMed Research

National Heart, Lung, and Blood Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Recruiting

Conditions: Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia
Cardiac Arrhythmias
Hematologic Malignancies
Mantle Cell Lymphoma
Sudden Cardiac Death
Chronic Lymphocytic Leukemia (CLL)

First Posted Date: 2023-02-13

Last Posted Date: 2025-05-21

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 135

Registration Number: NCT05724121

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease

Active, not recruiting

Conditions: Sickle Cell Anemia
Sickle Cell Thalassemia
Sickle Cell Syndrome Variant
Hbss
Hbsc
Sickle Beta Zero Thalassemia
Sickle Beta Thalassemia
Sickle Cell Pain

First Posted Date: 2023-01-09

Last Posted Date: 2025-04-16

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 6

Registration Number: NCT05675436

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial

Not Applicable

Active, not recruiting

Conditions: Aortic Valve Failure
Valvular Heart Disease

Interventions: Device: TELLTALE BASILICA procedure

First Posted Date: 2022-12-28

Last Posted Date: 2025-04-08

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 139

Registration Number: NCT05666713

Locations: 🇺🇸
California Pacific Med Ctr, San Francisco, California, United States
🇺🇸
Rochester Regional Health, Rochester, New York, United States
🇺🇸
University of Colorado Health, Fort Collins, Colorado, United States

and more 7 locations

Exploring Near Infrared Spectroscopy (NIRS) Technologies for Assessment of Muscle Physiology, Tissue Oxygenation, and Blood Flow in Patients With Sickle Cell Disease (SCD)

Not Applicable

Completed

Conditions: SCD

Interventions: Diagnostic Test: Non-Invasive Infrared Spectroscopy

First Posted Date: 2022-11-03

Last Posted Date: 2025-05-15

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 49

Registration Number: NCT05604547

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias

Phase 2

Conditions: Immune Mediated Thrombocytopenia
Chronic GVHD
Immune Mediated Anemia

Interventions: Drug: fostamatinib

First Posted Date: 2022-08-22

Last Posted Date: 2025-05-21

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 20

Registration Number: NCT05509582

Locations: 🇺🇸
Atrium Health, Charlotte, North Carolina, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias

Phase 2

Recruiting

Conditions: Immune Mediated Anemia
Immune Mediated Thrombocytopenia
Chronic GVHD

Interventions: Drug: fostamatinib

First Posted Date: 2022-08-16

Last Posted Date: 2025-05-16

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 20

Registration Number: NCT05502783

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Controls and Healthy Vasculature Initiative

Recruiting

Conditions: Healthy Volunteers
Vascular And Immunologic Diseases

First Posted Date: 2022-06-03

Last Posted Date: 2025-03-19

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1000

Registration Number: NCT05403151

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

NHLBI-Emory Advanced Cardiac CT Reconstruction

Not yet recruiting

Conditions: Structural Heart Disease

First Posted Date: 2022-05-13

Last Posted Date: 2025-05-21

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1000

Registration Number: NCT05372627

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
Emory University Midtown Hospital, Atlanta, Georgia, United States

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Phase 1

Active, not recruiting

Conditions: Sickle Cell Anemia
Beta Thalassemia

Interventions: Radiation: TBI
Drug: Hydroxyurea
Biological: briquilimab
Drug: Filgrastim (G-CSF)
Drug: Sirolimus
Biological: Alemtuzumab
Drug: Plerixafor

First Posted Date: 2022-05-03

Last Posted Date: 2025-03-26

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 40

Registration Number: NCT05357482

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

The Effect of Inflammation in Heart Failure

Phase 2

Withdrawn

Conditions: Heart Failure
Inflammation
Myocardial Dysfunction

Interventions: Device: MRI scan
Drug: Dapagliflozin
Device: CMR imaging

First Posted Date: 2022-04-15

Last Posted Date: 2022-06-27

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT05330013

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy